BYSI
BeyondSpring Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.62
−0.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 1.4M |
| Cost of Revenue | 38.0K | 87.0K | — | 302.0K | — |
| Gross Profit | (38.0K) | (87.0K) | — | (302.0K) | 1.4M |
| Operating Expenses | |||||
| R&D Expense | 4.6M | 4.4M | 2.6M | 7.3M | 25.6M |
| SG&A Expense | 3.8M | 4.6M | 6.1M | 7.5M | 13.0M |
| General & Admin Expense | 3.8M | 4.6M | 6.1M | — | 13.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (38.0K) | (87.0K) | — | — | — |
| Total Operating Expenses | 8.3M | 8.9M | 8.8M | 14.8M | 38.6M |
| Cost and Expenses | 8.3M | 8.9M | 8.8M | 15.1M | 38.6M |
| Operating Income (EBIT) | (8.3M) | (8.9M) | (8.8M) | (15.1M) | (37.2M) |
| Non-Operating | |||||
| Interest Income | 45.0K | 78.0K | 59.0K | 421.0K | 195.0K |
| Interest Expense | — | — | — | — | 17.0K |
| Net Interest Income | 45.0K | 78.0K | 59.0K | 421.0K | 178.0K |
| Other Non-Op Income/Expense | 335.0K | 320.0K | (15.0K) | 1.2M | 1.1M |
| Non-Operating Income (excl Interest) | (335.0K) | (320.0K) | 15.0K | (1.2M) | (1.1M) |
| EBT (Pre-Tax Income) | (8.0M) | (8.6M) | (8.8M) | (13.9M) | (36.1M) |
| Income Tax Expense | 4.3M | 90.0K | 96.0K | 92.0K | 163.0K |
| Bottom Line | |||||
| Net Income | (6.7M) | (8.0M) | (11.1M) | (21.0M) | (33.3M) |
| Earnings from Cont. Ops | (12.3M) | (8.7M) | (8.9M) | (14.0M) | (36.3M) |
| Earnings from Discont. Ops | (6.9M) | 481.0K | (2.6M) | (7.9M) | — |
| Bottom Line Net Income | (6.7M) | (8.0M) | (8.5M) | (21.0M) | (33.3M) |
| Per Share | |||||
| Basic EPS | ($0.17) | ($0.20) | ($0.28) | ($0.54) | ($0.85) |
| Diluted EPS | ($0.17) | ($0.20) | ($0.28) | ($0.54) | ($0.85) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.03 |
| Shares | |||||
| Basic Shares Outstanding | 41.1M | 40.4M | 39.7M | 39.0M | 39.1M |
| Diluted Shares Outstanding | 41.1M | 40.4M | 39.7M | 39.0M | 39.1M |
| Profitability Metrics | |||||
| EBITDA | (7.9M) | (8.5M) | (8.5M) | (13.6M) | (35.0M) |
| D&A | 141.0K | 87.0K | 285.0K | 302.0K | 1.1M |
| EBIT | (8.0M) | (8.6M) | (8.8M) | (13.9M) | (36.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026